Ally Bridge Group (NY) LLC — 13F Holdings & Portfolio
CIK 1822947 · latest 13F-HR filed 2026-05-18
Ally Bridge Group (NY) LLC manages $123.8M in 13F-reported U.S. long-equity assets across 28 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PRAX (8.54%), NERV (8.06%), SLNO (5.41%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 10 new positions, exited 2, added to 7, and trimmed 3.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$123.8M
Long-equity book
28
Distinct positions
2026-03-31
Filed 2026-05-18
+10 / −2 / ↑7 / ↓3
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- PRAXIS PRECISION MEDICINES I$4.7M +80.4%
- PROMIS NEUROSCIENCES INC$3.6M +209.1%
- OVID THERAPEUTICS INC$3.3M +115.0%
- MINERVA NEUROSCIENCES INC$3.3M +49.9%
- SOLID BIOSCIENCES INC$3.2M +136.7%
Top Trims
- ABIVAX SA-$5.7M -60.2%
- INVENTIVA SA-$2.8M -40.7%
- SOLENO THERAPEUTICS INC-$1.1M -13.9%
New Positions
- COMPASS PATHWAYS PLC$5.8M
- TARSUS PHARMACEUTICALS INC$5.7M
- CYTOMX THERAPEUTICS INC.$4.2M
- PERSPECTIVE THERAPEUTICS INC$3.9M
- ALUMIS INC$3.7M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $10.6M | 8.54% | 32,810 | SH |
| 2 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $10.0M | 8.06% | 1,655,500 | SH |
| 3 | SOLENO THERAPEUTICS INC | SLNO | 834203309 | $6.7M | 5.41% | 200,000 | SH |
| 4 | SOLENO THERAPEUTICS INC Put | SLNO | 834203309 | $6.7M | 5.41% | 200,000 | SH |
| 5 | OVID THERAPEUTICS INC | OVID | 690469101 | $6.3M | 5.05% | 2,818,459 | SH |
| 6 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $5.8M | 4.67% | 1,045,000 | SH |
| 7 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $5.7M | 4.58% | 80,859 | SH |
| 8 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $5.5M | 4.46% | 766,974 | SH |
| 9 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $5.3M | 4.25% | 414,219 | SH |
| 10 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $5.1M | 4.10% | 161,000 | SH |
| 11 | UNIQURE NV Call | QURE | N90064101 | $4.9M | 3.96% | 300,000 | SH |
| 12 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $4.8M | 3.86% | 660,375 | SH |
| 13 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $4.2M | 3.42% | 900,000 | SH |
| 14 | INVENTIVA SA | IVA | 46124U107 | $4.1M | 3.34% | 745,300 | SH |
| 15 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $3.9M | 3.12% | 926,557 | SH |
| 16 | ABIVAX SA | ABVX | 00370M103 | $3.8M | 3.03% | 33,712 | SH |
| 17 | ALUMIS INC | ALMS | 022307102 | $3.7M | 2.97% | 166,959 | SH |
| 18 | UROGEN PHARMA LTD | URGN | M96088105 | $3.6M | 2.94% | 202,124 | SH |
| 19 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $3.5M | 2.80% | 113,899 | SH |
| 20 | MAZE THERAPEUTICS INC Call | MAZE | 578784100 | $3.0M | 2.41% | 100,000 | SH |
| 21 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $2.8M | 2.28% | 817,939 | SH |
| 22 | COMPASS THERAPEUTICS INC Call | CMPX | 20454B104 | $2.6M | 2.14% | 500,000 | SH |
| 23 | COMPASS THERAPEUTICS INC Call | CMPX | 20454B104 | $2.6M | 2.14% | 500,000 | SH |
| 24 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $2.2M | 1.80% | 1,325,000 | SH |
| 25 | REPLIMUNE GROUP INC Call | REPL | 76029N106 | $1.9M | 1.53% | 246,900 | SH |
| 26 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $1.8M | 1.45% | 526,315 | SH |
| 27 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $1.5M | 1.18% | 210,525 | SH |
| 28 | KARYOPHARM THERAPEUTICS INC Call | KPTI | 48576U205 | $1.4M | 1.12% | 250,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-18 | $123.8M | 28 | 0001193125-26-227559 |
| 2025-12-31 | 2026-02-17 | $96.0M | 20 | 0001193125-26-055035 |
| 2025-09-30 | 2025-11-14 | $164.2M | 25 | 0001193125-25-283054 |